iifl-logo

Ipca Laboratories Ltd Half Yearly Results

1,438.2
(-0.64%)
Nov 20, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Sept-2025Mar-2025Sept-2024Mar-2024Sept-2023

Gross Sales

4,865.35

4,492.06

4,447.53

4,085.87

3,619.17

Excise Duty

0

0

0

0

0

Net Sales

4,865.35

4,492.06

4,447.53

4,085.87

3,619.17

Other Operating Income

0

0

0

0

0

Other Income

60.52

45.93

46.87

41.37

83.4

Total Income

4,925.87

4,537.99

4,494.4

4,127.24

3,702.57

Total Expenditure

3,962.27

3,805.17

3,613.33

3,501.35

2,990.28

PBIDT

963.6

732.82

881.07

625.89

712.29

Interest

38.12

38.32

46.61

62.77

75.5

PBDT

925.48

694.5

834.46

563.12

636.79

Depreciation

203.39

198.58

199.24

197.63

159.61

Minority Interest Before NP

0

0

0

0

0

Tax

204.26

189.69

182.36

138.35

171.83

Deferred Tax

-0.09

-36.88

8.44

1.58

1.7

Reported Profit After Tax

517.92

343.11

444.42

225.56

303.65

Minority Interest After NP

-2.36

24.39

23.17

-17.14

-7.29

Net Profit after Minority Interest

515.78

315.96

421.72

239.47

307.88

Extra-ordinary Items

-41.78

-205.05

0

-68.26

-25.13

Adjusted Profit After Extra-ordinary item

557.56

521.01

421.72

307.73

333.01

EPS (Unit Curr.)

20.33

12.45

16.62

9.44

12.14

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

200

0

200

Equity

25.37

25.37

25.37

25.37

25.37

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

19.8

16.31

19.81

15.31

19.68

PBDTM(%)

-

-

-

-

-

PATM(%)

10.64

7.63

9.99

5.52

8.39

Ipca Labs.: Related NEWS

Ipca Laboratories to Consolidate US Generics Business; Shares Up 1%

This consolidation aims to streamline all of Ipca Group's US generics formulations under a single entity, enhancing operational efficiency.

23 Sep 2024|03:01 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.